Combination Therapy in Urological Malignancy

1. Front Matter

   Pages i-xiii

   PDF

2. Radiation Therapy: its Integration with Surgery and Chemotherapy in the Management of Patients with Urological Malignancy

   • W. U. Shipley

   Pages 1-23

3. Chemotherapy

   • G. Stoter, C. J. Rodenburg

   Pages 25-28

4. Immunotherapy

   • S. A. Brosman

   Pages 29-49

5. Carcinoma of the Kidney

   • T. Ebert, R. Ackermann

   Pages 51-81

6. Intravesical Treatment of Superficial Bladder Cancer

   • W. W. Bonney

   Pages 83-93

7. Management of Invasive Bladder Neoplasms

   • Cora N. Sternberg, H. I. Scher

   Pages 95-118

8. Carcinoma of the Prostate — Non-metastatic Disease

   • F. S. Freiha

   Pages 119-141

9. Carcinoma of the Prostate — Metastatic Disease

   • M. Pavone-Macaluso

   Pages 143-172

10. The Staging and Treatment of Testicular Cancer: Management of Stage I Disease

    • Sophie D. Fosså, A. Horwich

    Pages 173-189

11. Chemotherapy in Disseminated Testicular Cancer

    • C. J. Rodenburg, G. Stoter

    Pages 191-198

12. Cancer of the Penis

    • W. G. Jones

    Pages 199-205

13. Surgical Preservation and Reconstruction

    • B. Goldwasser, J. Ramon, O. Nativ

    Pages 207-223

14. Clinical Trials in Genitourinary Oncology: What Have They Achieved?

    • D. Raghavan, I. F. Tannock

    Pages 225-253

15. Quality of Life and Palliation Treatment in Urological Cancer

    • Sophie D. Fosså, N. K. Aaronson, F. Calais da Silva

    Pages 255-263

16. The Cost of Treatment

    • D. W. W. Newling, J. Hutton

    Pages 265-274

17. Back Matter

    Pages 275-278

    PDF

Any discussion of the present success in management of urological cancers evokes a mixed response. Oncologists and urologists can enjoy the success with chemotherapy for testicular cancers but cannot forget the dismal results with any form of treatment, other than surgery, for renal carcinoma. But these are the less frequent urolegi­ cal tumours: what are the attitudes to the more common prostate and bladder cancers. Intensive study, many clinical trials and much debate lead us to the conclusion that we understand them better, we can tailor the treatment more appropriately to the individual patient but there remains some uncertainty as to the overall success that we have achieved. There have been no striking changes in the 5-year survival data. Clinicians tend to see their success in terms of their special interest. Radiotherapists point to their success in stage-reduction but what are we to do with the many patients whose tumour is unaltered by radiotherapy. Urological surgeons, and especially those who are still influenced by the shadow of Halsted, point to their success in excising the cancer but apart from that highly selected group, what are we to do for the very large number of patients for whom surgery is inappro­ priate. Bystanders can only watch and listen to the arguments for and against these views.

• Staging
• Tumor
• cancer
• carcinoma
• chemotherapy
• clinical trial
• immunotherapy
• kidney
• metastatic disease
• oncology
• prostate
• quality of life
• radiation
• radiation therapy
• surgery
• Radiaton Oncology

• St James’s University Hospital, Leeds, UK

  Philip H. Smith

Policies and ethics